Avanir Pharmaceuticals (AVNR) Stock Falls Off After Yesterday's Gain

NEW YORK (TheStreet) -- Avanir Pharmaceuticals  (AVNR) spiked Wednesday afternoon after a court ruled in the company's favor in a patent litigation case, but the shares had fallen off considerably by the close of trading Thursday.

The stock dropped 6.63%, or 33 cents, to $4.65 at the closing bell. More than 11.2 million shares changed hands to easily surpass the average volume of 2,408,670. The stock had a range of $4.45 to $5.06 for the day and holds a 52-week range of $2.62 to $6.

On Wednesday, the U.S. District Court for the District of Delaware ruled in the company's favor in its patent infringement lawsuit against Par Pharmaceuticals and Impax Laboratories over NUEDEXTA.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The latter two companies had Abbreviated New Drug Applications for generic versions of NUEDEXTA capsules for the treatment of pseudobulbar affect, a medical disorder characterized by sudden and uncontrollable episodes of crying or laughing. After a six-day bench trial, the court ruled in Avanir's favor.

"We are very pleased with the Court's decision, as it confirms our continued belief in the strength of the patents covering NUEDEXTA," said Avanir President and CEO Keith A. Katkin in a statement. "Our focus remains on making NUEDEXTA available to patients suffering from the debilitating condition of PBA. This decision provides twelve-plus years of market exclusivity for NUEDEXTA."  

NUEDEXTA is still the only FDA-approved item for pseudobulbar affect treatment, according to Avanir's statement.
AVNR Chart

AVNR data by YCharts

If you liked this article you might like

Develop Biotech 'Buy-Sell' Strategy

Develop Biotech 'Buy-Sell' Strategy

Two Small-Cap Biotechs To Consider

Two Small-Cap Biotechs To Consider

Next Year's Stock Returns: 5% or 15%?

Next Year's Stock Returns: 5% or 15%?

Updating a Small Speculative Play

Updating a Small Speculative Play

Three Large-Cap Growth Stocks

Three Large-Cap Growth Stocks